LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article ; Online: Generation of mesenchymal stem cells as a medicinal product in organ transplantation.

Verbeek, Richard

Current opinion in organ transplantation

2013 Volume 18, Issue 1, Page(s) 65–70

Abstract: Purpose of review: Mesenchymal stem cells (MSCs) are emerging as an alternative treatment in solid-organ transplantation. The use of MSCs as a therapeutic product requires the translation of basic research protocols into a production process under good ... ...

Abstract	Purpose of review: Mesenchymal stem cells (MSCs) are emerging as an alternative treatment in solid-organ transplantation. The use of MSCs as a therapeutic product requires the translation of basic research protocols into a production process under good manufacturing practice (GMP) to obtain a safe product of high quality. This requires a different mindset from the academic setting of changing protocols into a well defined, controlled and documented process. This review describes some of the challenges faced by culturing MSCs as a medicinal product. Recent findings: Clinical-grade MSCs are used in the clinical trials and proved to be safe as a medicinal product. Because of the differences in the type of MSCs and in the production process, clinical outcome is not always comparable. New standardized methods in the culture condition such as the use of alternatives for fetal bovine serum (FBS), standardized plating densities or the use of bioreactors may further standardize the production process. Summary: To generate MSCs as a medicinal product in organ transplantation, regulation requires that MSCs have to be generated under GMP. During the whole production process, all critical steps should be known and described. Further steps should be taken to optimize and standardize the production process.
MeSH term(s)	Animals ; Biological Products/standards ; Cattle ; Cell Culture Techniques/methods ; Cell Culture Techniques/standards ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells/cytology ; Organ Transplantation ; Reference Standards
Chemical Substances	Biological Products
Language	English
Publishing date	2013-02
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1390429-2
ISSN	1531-7013 ; 1087-2418
ISSN (online)	1531-7013
ISSN	1087-2418
DOI	10.1097/MOT.0b013e32835c2998
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals.

Reijers, Joannes A A / Malone, Karen E / Bajramovic, Jeffrey J / Verbeek, Richard / Burggraaf, Jacobus / Moerland, Matthijs

British journal of clinical pharmacology

2019 Volume 85, Issue 7, Page(s) 1418–1426

Abstract: Drug safety is an important issue, especially in the experimental phases of development. Adverse immunostimulation (AI) is sometimes encountered following treatment with biopharmaceuticals, which can be life-threatening if it results in a severe systemic ...

Abstract	Drug safety is an important issue, especially in the experimental phases of development. Adverse immunostimulation (AI) is sometimes encountered following treatment with biopharmaceuticals, which can be life-threatening if it results in a severe systemic inflammatory reaction. Biopharmaceuticals that unexpectedly induce an inflammatory response still enter the clinic, even while meeting all regulatory requirements. Impurities (of microbial origin) in biopharmaceuticals are an often-overlooked cause of AI. This demonstrates that the current guidelines for quality control and safety pharmacology testing are not flawless. Here, based on two case examples, several shortcomings of the guidelines are discussed. The most important of these are the lack of sensitivity for impurities, lack of testing for pyrogens other than endotoxin, and the use of insensitive animal species and biomarkers in preclinical investigations. Moreover, testing for the immunotoxicity of biopharmaceuticals is explicitly not recommended by the international guidelines. Publication of cases of AI is pivotal, both to increase awareness and to facilitate scientific discussions on how to prevent AI in the future.
MeSH term(s)	Animals ; Biological Products/adverse effects ; Biological Products/immunology ; Biological Products/standards ; Drug Contamination ; Endotoxins/isolation & purification ; Guidelines as Topic ; Humans ; Immunomodulation/drug effects ; Pyrogens/isolation & purification ; Quality Control
Chemical Substances	Biological Products ; Endotoxins ; Pyrogens
Language	English
Publishing date	2019-05-29
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	188974-6
ISSN	1365-2125 ; 0306-5251 ; 0264-3774
ISSN (online)	1365-2125
ISSN	0306-5251 ; 0264-3774
DOI	10.1111/bcp.13938
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1118: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Therapeutic Intervention in Multiple Sclerosis with Alpha B-Crystallin: A Randomized Controlled Phase IIa Trial.

van Noort, Johannes M / Bsibsi, Malika / Nacken, Peter J / Verbeek, Richard / Venneker, Edna H G

PloS one

2015 Volume 10, Issue 11, Page(s) e0143366

Abstract: Unlabelled: As a molecular chaperone and activator of Toll-like receptor 2-mediated protective responses by microglia and macrophages, the small heat shock protein alpha B-crystallin (HspB5) exerts therapeutic effects in different animal models for ... ...

Abstract	Unlabelled: As a molecular chaperone and activator of Toll-like receptor 2-mediated protective responses by microglia and macrophages, the small heat shock protein alpha B-crystallin (HspB5) exerts therapeutic effects in different animal models for neuroinflammation, including the model for multiple sclerosis (MS). Yet, HspB5 can also stimulate human antigen-specific memory T cells to release IFN-γ, a cytokine with well-documented detrimental effects during MS. In this study, we explored in a Phase IIa randomized clinical trial the therapeutic application of HspB5 in relapsing-remitting MS (RR-MS), using intravenous doses sufficient to support its protective effects, but too low to trigger pathogenic memory T-cell responses. These sub-immunogenic doses were selected based on in vitro analysis of the dose-response profile of human T cells and macrophages to HspB5, and on the immunological effects of HspB5 in healthy humans as established in a preparatory Phase I study. In a 48-week randomized, placebo-controlled, double-blind Phase IIa trial, three bimonthly intravenous injections of 7.5, 12.5 or 17.5 mg HspB5 were found to be safe and well tolerated in RR-MS patients. While predefined clinical endpoints did not differ significantly between the relatively small groups of MS patients treated with either HspB5 or placebo, repeated administration especially of the lower doses of HspB5 led to a progressive decline in MS lesion activity as monitored by magnetic resonance imaging (MRI), which was not seen in the placebo group. Exploratory linear regression analysis revealed this decline to be significant in the combined group receiving either of the two lower doses, and to result in a 76% reduction in both number and total volumes of active MRI lesions at 9 months into the study. These data provide the first indication for clinical benefit resulting from intervention in RR-MS with HspB5. Trial registration: ClinicalTrials.gov Phase I: NCT02442557; Phase IIa: NCT02442570.
MeSH term(s)	Adult ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Treatment Outcome ; alpha-Crystallin B Chain/administration & dosage ; alpha-Crystallin B Chain/therapeutic use
Chemical Substances	alpha-Crystallin B Chain
Language	English
Publishing date	2015
Publishing country	United States
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0143366
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Guidelines for STEMI.

O'Donnell, Cathal / Verbeek, Richard

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

2005 Volume 172, Issue 11, Page(s) 1425–6; author reply 1426

MeSH term(s)	Angioplasty, Balloon ; Critical Care/standards ; Emergency Medical Technicians ; Humans ; Myocardial Infarction/therapy ; Referral and Consultation ; Time Factors
Language	English
Publishing date	2005-05-24
Publishing country	Canada
Document type	Comment ; Letter
ZDB-ID	215506-0
ISSN	1488-2329 ; 0008-4409 ; 0820-3946
ISSN (online)	1488-2329
ISSN	0008-4409 ; 0820-3946
DOI	10.1503/cmaj.1041729
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.136: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Field Implementation of Remote Ischemic Conditioning in ST-Segment-Elevation Myocardial Infarction: The FIRST Study.

Cheskes, Sheldon / Koh, Maria / Turner, Linda / Heslegrave, Ronald / Verbeek, Richard / Dorian, Paul / Scales, Damon C / Singh, Bob / Amlani, Shy / Natarajan, Madhu / Morrison, Laurie J / Kakar, Priya / Nowickyj, Roman / Lawrence, Michael / Cameron, Jennifer / Ko, Dennis T

The Canadian journal of cardiology

2019 Volume 36, Issue 8, Page(s) 1278–1288

Abstract: Background: Remote ischemic conditioning (RIC) is a noninvasive therapeutic strategy that uses brief cycles of blood pressure cuff inflation and deflation to protect the myocardium against ischemia-reperfusion injury. We sought to compare major adverse ... ...

Abstract	Background: Remote ischemic conditioning (RIC) is a noninvasive therapeutic strategy that uses brief cycles of blood pressure cuff inflation and deflation to protect the myocardium against ischemia-reperfusion injury. We sought to compare major adverse cardiovascular events (MACE) for patients who received RIC before PCI for ST-segment-elevation myocardial infarction (STEMI) compared with standard care. Methods: We conducted a pre- and postimplementation study. In the preimplementation phase, STEMI patients were taken directly to the PCI lab. After implementation, STEMI patients received 4 cycles of RIC by paramedics or emergency department staff before PCI. The primary outcome was MACE at 90 days. Secondary outcomes included MACE at 30, 60, and 180 days. Inverse probability of treatment weighting using propensity scores estimated causal effects independent from baseline covariables. Results: A total of 1667 (866 preimplementation, 801 postimplementation) patients were included. In the preimplementation phase, 13.4% had MACE at 90 days compared with 11.8% in the postimplementation phase (odds ratio [OR] 0.86, 95% CI 0.62-1.21). There were no significant differences in MACE at 30, 60, and 180 days. Patients presenting with cardiogenic shock or cardiac arrest before PCI were less likely to have MACE at 90 days (42.7% pre vs 27.8% post) if they received RIC before PCI (OR 0.52, 95% CI 0.27-0.98). Conclusions: A strategy of RIC before PCI for STEMI did not reduce 90-day MACE. Future research should explore the impact of RIC before PCI for longer-term clinical outcomes and for patients presenting with cardiogenic shock or cardiac arrest.
MeSH term(s)	Blood Pressure/physiology ; Electrocardiography ; Female ; Follow-Up Studies ; Humans ; Ischemic Preconditioning, Myocardial/methods ; Male ; Middle Aged ; Percutaneous Coronary Intervention ; Retrospective Studies ; ST Elevation Myocardial Infarction/complications ; ST Elevation Myocardial Infarction/diagnosis ; ST Elevation Myocardial Infarction/therapy ; Shock, Cardiogenic/etiology ; Shock, Cardiogenic/prevention & control ; Telemedicine/methods ; Time Factors ; Treatment Outcome
Language	English
Publishing date	2019-11-27
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	632813-1
ISSN	1916-7075 ; 0828-282X
ISSN (online)	1916-7075
ISSN	0828-282X
DOI	10.1016/j.cjca.2019.11.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2150: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice.

Verbeek, Richard / van Tol, Eric A F / van Noort, Johannes M

Biochemical pharmacology

2005 Volume 70, Issue 2, Page(s) 220–228

Abstract: Flavonoids are food components that appear to have potential beneficial health effects. There is a range of in vitro studies supporting the anti-oxidant and anti-inflammatory properties of flavonoids. Previously, we demonstrated that in vitro flavonoids, ...

Abstract	Flavonoids are food components that appear to have potential beneficial health effects. There is a range of in vitro studies supporting the anti-oxidant and anti-inflammatory properties of flavonoids. Previously, we demonstrated that in vitro flavonoids, including luteolin and apigenin, inhibit proliferation and IFN-gamma production by murine and human autoimmune T cells. In the present study, we examined the effects of oral flavonoids as well as of curcumin on autoimmune T cell reactivity in mice and on the course of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. Continuous oral administration of flavonoids significantly affected antigen-specific proliferation and IFN-gamma production by lymph node-derived T cells following immunization with an EAE-inducing peptide. Both luteolin and apigenin suppress proliferative responses as they did in vitro, whereas IFN-gamma production on the other hand was enhanced. Other flavonoids exerted differential effects on proliferation and IFN-gamma production. The effects of flavonoids and curcumin on EAE were assessed using either passive transfer of autoimmune T cells or active disease induction. In passive EAE, flavonoids led to delayed recovery of clinical symptoms rather than to any reduction in disease. In active EAE, the effects were less pronounced but also, in this case, the flavonoid hesperitin delayed recovery. Oral curcumin had overall mild but beneficial effects. Our results indicate that oral flavonoids fail to beneficially influence the course of EAE in mice but, instead, suppress recovery from acute inflammatory damage.
MeSH term(s)	Administration, Oral ; Animals ; Cells, Cultured ; Encephalomyelitis, Autoimmune, Experimental/chemically induced ; Encephalomyelitis, Autoimmune, Experimental/pathology ; Encephalomyelitis, Autoimmune, Experimental/physiopathology ; Female ; Flavonoids/administration & dosage ; Flavonoids/adverse effects ; Glycosides/administration & dosage ; Growth Inhibitors/administration & dosage ; Growth Substances/administration & dosage ; Luteolin/administration & dosage ; Mice ; Mice, Inbred Strains ; Quercetin/administration & dosage ; Recovery of Function/drug effects ; Recovery of Function/physiology ; T-Lymphocytes/cytology ; T-Lymphocytes/drug effects ; T-Lymphocytes/pathology
Chemical Substances	Flavonoids ; Glycosides ; Growth Inhibitors ; Growth Substances ; alhagidin ; morin (8NFQ3F76WR) ; Quercetin (9IKM0I5T1E) ; Luteolin (KUX1ZNC9J2) ; fisetin (OO2ABO9578)
Language	English
Publishing date	2005-07-15
Publishing country	England
Document type	Comparative Study ; Journal Article
ZDB-ID	208787-x
ISSN	1873-2968 ; 0006-2952
ISSN (online)	1873-2968
ISSN	0006-2952
DOI	10.1016/j.bcp.2005.04.041
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 19: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Paramedic contact to balloon in less than 90 minutes: a successful strategy for st-segment elevation myocardial infarction bypass to primary percutaneous coronary intervention in a canadian emergency medical system.

Cheskes, Sheldon / Turner, Linda / Foggett, Ruth / Huiskamp, Maud / Popov, Dean / Thomson, Sue / Sage, Greg / Watson, Randy / Verbeek, Richard

Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors

2011 Volume 15, Issue 4, Page(s) 490–498

Abstract: Introduction: Few systems worldwide have achieved the benchmark time of less than 90 minutes from emergency medical services (EMS) contact to balloon inflation (E2B) for patients sustaining ST-segment elevation myocardial infarction (STEMI). We describe ...

Abstract	Introduction: Few systems worldwide have achieved the benchmark time of less than 90 minutes from emergency medical services (EMS) contact to balloon inflation (E2B) for patients sustaining ST-segment elevation myocardial infarction (STEMI). We describe a successful EMS systems approach using a combination of paramedic and 12-lead electrocardiogram (ECG) software interpretation to activate a STEMI bypass protocol. Objectives: To determine the proportion of patients who met the benchmark of E2B in less than 90 minutes after institution of a regional paramedic activated STEMI bypass to primary PCI protocol. Methods: We conducted a before-and-after observational cohort study over a 24-month period ending December 31, 2009. Included were all patients diagnosed with STEMI by paramedics trained in ECG acquisition and interpretation and transported by EMS. In the "before" phase of the study, paramedics gave emergency departments (EDs) advance notification of the arrival of STEMI patients and took the patients to the ED of the PCI center. In the "after" phase of the study, paramedics activated a STEMI bypass protocol in which STEMI patients were transported directly to the PCI suite, bypassing the local hospital EDs. Transmission of ECGs did not occur in either phase of the study. Results: We compared the times for 95 STEMI patients in the before phase with the times for 80 STEMI patients in the after phase. The proportion for whom E2B was less than 90 minutes increased from 28.4% before to 91.3% after (p < 0.001). Median E2B time decreased from 107 minutes (interquartile range [IQR] = 30) before to 70 minutes (IQR = 24) after. Median D2B time decreased from 83 minutes (IQR = 34) before to 35 minutes (IQR = 19) after. Median E2D time increased from 21 minutes (IQR = 8) before to 32 minutes (IQR = 17) after. Median differences between phases were significant at p < 0.001. The rate of false-positive PCI laboratory activation during the after phase of the study was 12.4%. Conclusions: The proportion of patients with E2B times less than 90 minutes significantly improved through the implementation of a paramedic-activated STEMI bypass protocol. Further study is required to determine whether these benefits are reproducible in other EMS systems.
MeSH term(s)	Angioplasty, Balloon, Coronary/methods ; Angioplasty, Balloon, Coronary/standards ; Benchmarking ; Clinical Protocols ; Electrocardiography ; Emergency Medical Services/manpower ; Emergency Medical Services/methods ; Emergency Medical Services/standards ; Emergency Medical Technicians ; Humans ; Myocardial Infarction/diagnosis ; Myocardial Infarction/therapy ; Ontario ; Time Factors
Language	English
Publishing date	2011-10
Publishing country	England
Document type	Journal Article
ZDB-ID	1461751-1
ISSN	1545-0066 ; 1090-3127
ISSN (online)	1545-0066
ISSN	1090-3127
DOI	10.3109/10903127.2011.598613
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Induction of EAE by T cells specific for alpha B-crystallin depends on prior viral infection in the CNS.

Verbeek, Richard / van Dongen, Henrike / Wawrousek, Eric F / Amor, Sandra / van Noort, Johannes M

International immunology

2007 Volume 19, Issue 3, Page(s) 277–285

Abstract: While myelin-reactive T cells are widely believed to play a pathogenic role in multiple sclerosis (MS), no substantial differences appear to exist in T-cell responses to myelin antigens between MS patients and healthy subjects. As an example, ... ...

Abstract	While myelin-reactive T cells are widely believed to play a pathogenic role in multiple sclerosis (MS), no substantial differences appear to exist in T-cell responses to myelin antigens between MS patients and healthy subjects. As an example, indistinguishable peripheral T-cell responses and serum antibody levels have been found in MS patients and healthy controls to alpha B-crystallin, a dominant antigen in MS-affected brain myelin. This suggests that additional factors are relevant in allowing myelin-reactive T cells to become pathogenic. In this study, we examined whether the inflammatory state of the CNS is relevant to the pathogenicity of alpha B-crystallin-specific T cells in mice. In normal mice, T-cell responses against alpha B-crystallin are limited by robust immunological tolerance. Reactive T cells were therefore generated in alpha B-crystallin-deficient mice, and these T cells were transferred into C57BL/6 recipients. While such a transfer in itself never induced any clinical signs of experimental autoimmune encephalomyelitis (EAE) in healthy recipient mice, acute EAE could be induced in animals that had been infected 7 days before with the avirulent A7(74) strain of Semliki Forest virus (SFV). SFV infection alone did not induce clinical disease, nor did it alter the expression levels of the target antigen. Our findings indicate that at least in mice, alpha B-crystallin-specific T cells can trigger EAE but only when prior viral infection has induced an inflammatory state in the CNS that helps recruit and activate T cells.
MeSH term(s)	Adoptive Transfer ; Alphavirus Infections/complications ; Alphavirus Infections/immunology ; Alphavirus Infections/virology ; Animals ; Cells, Cultured ; Central Nervous System Viral Diseases/complications ; Central Nervous System Viral Diseases/immunology ; Central Nervous System Viral Diseases/virology ; Encephalomyelitis, Autoimmune, Experimental/immunology ; Encephalomyelitis, Autoimmune, Experimental/virology ; Immune Tolerance ; Inflammation Mediators/immunology ; Lymphocyte Activation ; Mice ; Mice, Biozzi ; Mice, Inbred C57BL ; Mice, Knockout ; Semliki forest virus ; Spinal Cord/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation ; Time Factors ; alpha-Crystallin B Chain/genetics ; alpha-Crystallin B Chain/immunology ; alpha-Crystallin B Chain/metabolism
Chemical Substances	Inflammation Mediators ; alpha-Crystallin B Chain
Language	English
Publishing date	2007-03
Publishing country	England
Document type	Journal Article
ZDB-ID	1013745-2
ISSN	1460-2377 ; 0953-8178
ISSN (online)	1460-2377
ISSN	0953-8178
DOI	10.1093/intimm/dxl144
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2619: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 70: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Establishing the Production of Male Schistosoma mansoni Cercariae for a Controlled Human Infection Model.

The Journal of infectious diseases

2018 Volume 218, Issue 7, Page(s) 1142–1146

Abstract: To accelerate the development of novel vaccines for schistosomiasis, we set out to develop a human model for Schistosoma mansoni infection in healthy volunteers. During natural infections, female schistosomes produce eggs that give rise to morbidity. ... ...

Abstract	To accelerate the development of novel vaccines for schistosomiasis, we set out to develop a human model for Schistosoma mansoni infection in healthy volunteers. During natural infections, female schistosomes produce eggs that give rise to morbidity. Therefore, we produced single-sex, male Schistosoma mansoni cercariae for human infection without egg production and associated pathology. Cercariae were produced in their intermediate snail hosts in accordance with the principles of good manufacturing practice (GMP). The application of GMP principles to an unconventional production process is a showcase for the controlled production of complex live challenge material in the European Union or under Food and Drug Administration guidance.
MeSH term(s)	Animals ; Cercaria ; Humans ; Male ; Schistosoma mansoni/immunology ; Schistosomiasis/parasitology ; Schistosomiasis/prevention & control ; Schistosomiasis mansoni/parasitology ; Schistosomiasis mansoni/prevention & control ; Snails/parasitology
Language	English
Publishing date	2018-06-14
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiy275
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.50: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy.

Hoogduijn, Martin J / Popp, Felix / Verbeek, Richard / Masoodi, Mojgan / Nicolaou, Anna / Baan, Carla / Dahlke, Marc-H

International immunopharmacology

2010 Volume 10, Issue 12, Page(s) 1496–1500

Abstract: There is growing interest in the use of mesenchymal stem cells (MSC) for immune therapy. Clinical trials that use MSC for treatment of therapy resistant graft versus host disease, Crohn's disease and organ transplantation have initiated. Nevertheless, ... ...

Abstract	There is growing interest in the use of mesenchymal stem cells (MSC) for immune therapy. Clinical trials that use MSC for treatment of therapy resistant graft versus host disease, Crohn's disease and organ transplantation have initiated. Nevertheless, the immunomodulatory effects of MSC are only partly understood. Clinical trials that are supported by basic research will lead to better understanding of the potential of MSC for immunomodulatory applications and to optimization of such therapies. In this manuscript we review some recent literature on the mechanisms of immunomodulation by MSC in vitro and animal models, present new data on the secretion of pro-inflammatory and anti-inflammatory cytokines, chemokines and prostaglandins by MSC under resting and inflammatory conditions and discuss the hopes and expectations of MSC-based immune therapy.
MeSH term(s)	Animals ; Clinical Trials as Topic ; Cytokines/immunology ; Cytokines/secretion ; Graft vs Host Disease/therapy ; Humans ; Immunotherapy/methods ; Mesenchymal Stromal Cells/immunology ; Prostaglandins/immunology ; Prostaglandins/secretion
Chemical Substances	Cytokines ; Prostaglandins
Language	English
Publishing date	2010-12
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2043785-7
ISSN	1878-1705 ; 1567-5769
ISSN (online)	1878-1705
ISSN	1567-5769
DOI	10.1016/j.intimp.2010.06.019
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5408: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito